Mirati Therapeutics to Present at 41st Annual Goldman Sachs Global Healthcare Conference

On June 5, 2020 Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, reported that it will participate in the upcoming 41st Annual Goldman Sachs Global Healthcare Conference on Thursday, June 11, 2020 (Press release, Mirati, JUN 5, 2020, View Source [SID1234560875]). Charles M. Baum, M.D., Ph.D., President and Chief Executive Officer at Mirati will represent the Company during the fireside chat at 1:20 p.m. EDT/ 10:20 a.m. PDT.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will be webcast and made available through the "Investors" section of the Mirati website at www.mirati.com. Replays will be made available for 90 days following the event.

Ionis Pharmaceuticals to present at upcoming virtual investor conferences

On June 5, 2020 Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in antisense therapeutics, reported that management will present a company overview at the following virtual investor conferences (Press release, Ionis Pharmaceuticals, JUN 5, 2020, View Source [SID1234560876]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

William Blair 40th Annual Growth Stock Conference on Wednesday, June 10, 2020;
Goldman Sachs 41st Annual Global Healthcare Conference on Wednesday, June 10, 2020; and
BMO 2020 Prescriptions for Success Healthcare Conference on Tuesday, June 23, 2020.
The above listed dates are subject to change. Details on presentation times or changes to presentation dates can be found on the Company’s website. Please check www.ionispharma.com for the latest information.

A live webcast of the presentations will be available on the Investors & Media section of the Ionis website. The replays will be available within 48 hours and will be archived for a limited time.

Chugai Files for Expanded Use of FoundationOne CDx Cancer Genomic Profile as a Companion Diagnostic of Lynparza for Metastatic Castration-Resistant Prostate Cancer with HRR-Related Gene Alterations

On June 5, 2020 hugai Pharmaceutical Co., Ltd. (TOKYO: 4519) reported that it filed an application with the Ministry of Health, Labour and Welfare for the expanded use of FoundationOne CDx Cancer Genomic Profile as a companion diagnostic for the PARP inhibitor, Lynparza (generic name: olaparib), for the treatment of homologous recombination repair mutated (HRRm) metastatic castration-resistant prostate cancer (mCRPC) (Press release, Chugai, JUN 5, 2020, View Source [SID1234560861]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Currently, various approaches are progressing to investigate new treatments for patients with mCRPC who are resistant to hormonal therapy and genomic medicine could become an important treatment option," said Dr. Osamu Okuda, Chugai’s President and COO. "Since HRR gene alterations are recognized to be identified in multiple genes, we believe FoundationOne CDx Cancer Genomic Profile will be a useful tool that can support physicians to identify patients who may benefit from treatment with Lynparza by comprehensively understanding patients’ genomic profiles."

The filing aims to expand the use as a companion diagnostic to identify patients who could benefit from Lynparza for the treatment of mCRPC with HRR related gene alterations, and have progressed following prior treatment with enzalutamide or abiraterone by detecting HRR related gene alterations. The efficacy and safety of Lynparza in mCRPC patients were investigated in the Phase III PROfound study. Lynparza is jointly developed and commercialized by AstraZeneca (LSE/STO/NYSE: AZN) and MSD (MSD: known as Merck & Co. inside the US and Canada).

Developed by Foundation Medicine Inc., FoundationOne CDx Cancer Genomic Profile is a next-generation sequencing based in vitro diagnostic device for the detection of substitutions, insertion and deletion alterations, and copy number alterations in 324 genes and select gene rearrangements, as well as genomic signatures including microsatellite instability (MSI) and tumor mutational burden (TMB) using DNA isolated from formalin-fixed, paraffin-embedded (FFPE) tumor tissue specimens. The program is available as a companion diagnostic for multiple molecular-targeted drugs approved in Japan.

As a leading company in the field of oncology, Chugai is committed to realize advanced personalized oncology care and contribute to patients and healthcare professionals through improving access to comprehensive genomic profiling.

Trademarks used or mentioned in this release are protected by laws.

Ryvu Therapeutics Signs a Grant Agreement for the Development of Targeted Immuno-oncology Therapy

On June 5, 2020 Ryvu Therapeutics (WSE: RVU), a clinical-stage biopharmaceutical company developing novel small molecule therapies that address emerging targets in oncology, reported that it has signed a grant agreement with the National Centre for Research and Development for the development of targeted immuno-oncology therapy (Press release, Ryvu Therapeutics, JUN 5, 2020, View Source [SID1234560877]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This grant provides Ryvu with almost USD 5.6 million of non-dilutive financing to discover, develop and select a clinical candidate targeting cancers which had been considered in the past as largely undruggable using rational approaches. Total net value of the project amounts to over USD 8.9 million and the anticipated project duration is until December 2023.

The aim of the project is development of a novel drug candidate, characterized in Phase I clinical study. The selected candidate should overcome the limitations of current immunotherapies, allowing effective and safe treatment options for patients with aggressive, refractory tumors. As a result of the conducted research, a small molecule immunomodulator of the patient’s response against own cancer cells, serving as a strictly personalized therapy, will be identified.

The project is already in progress and the analysis of publicly available and commercial databases has confirmed that currently most advanced, compounds developed by Ryvu in this project, have the potential to become first-in-class medicines.

"Immuno-oncology has undeniably revolutionized the approach to cancer treatment. Immunotherapies offer a new chance to create an effective therapy for patients with aggressive, treatment-resistant cancers. With the financial support of the National Centre for Research and Development we can continue our research in the immune-oncology area at a full speed," commented Krzysztof Brzozka, PhD, Chief Scientific Officer and Executive VP at Ryvu Therapeutics.

Arvinas to Present Virtually at the Goldman Sachs 41st Annual Global Healthcare Conference

On June 5, 2020 Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, reported that Ron Peck, M.D., Chief Medical Officer, will participate in a fireside chat at the Goldman Sachs 41st Annual Global Healthcare Conference on Thursday, June 11 at 4:40 p.m. ET (Press release, Arvinas, JUN 5, 2020, View Source [SID1234560862]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of the presentation will be available here and on the Company’s website at www.arvinas.com. A replay of the webcast will be archived on the Arvinas website for 30 days following the presentation.